Compare ABRDN Physical Gold Shares ETF (SGOL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Smith & Nephew plc — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Smith & Nephew plc for 121 Days on average.
| SGOL | SNN | |
|---|---|---|
Market Cap | $7.03B | $11.10B |
Volume | 2,350,550 | 1,051,703 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $37.17 |
52-Week Low | $37.54 | $26.42 |
Typical Hold Time | 57 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.92, up 2.31% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks key financial ratio data, making fundamental assessment difficult. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices under pressure from rising rates but finding some support from softer inflation data.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from interest rates. Investment opportunity hinges on gold's safe-haven appeal if economic uncertainty rises, but risks include persistent rate hikes and dollar strength dampening gold demand. Without current fundamentals, valuation is unclear.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
